Canada's Natural Health Products Regulations Are Changing: What the Self-Care Framework Means for NHP Manufacturers

When Health Canada’s Natural Health Products Fee Regulations came into force on September 1, 2023, most NHP manufacturers noticed the change in their accounting departments before they noticed it in their compliance programs. For the first time in nearly 20 years — since the original Natural Health Products Regulations took effect in January 2004 — applying for a product license actually cost something. Class I product license applications now carry a base fee of approximately $1,099. Class II applications run closer to $3,100. Site license applications add another several thousand dollars on top of that.

Fees are rarely the interesting part of a regulatory shift. But in this case, they matter for a specific reason: they signal that Health Canada is treating NHPs with the same revenue-and-accountability logic it applies to pharmaceutical drugs. And that shift in posture is just the visible edge of a much deeper regulatory modernization effort that has been quietly accelerating since at least 2016.

If your organization manufactures, imports, or packages natural health products for the Canadian market, this is the regulatory moment that deserves your attention — not because any single change is catastrophic, but because several changes are moving in the same direction at the same time.

Why the 2023 NHP Fee Regulations Marked a Real Turning Point

The NHP cost-recovery program wasn’t a surprise. Health Canada had been consulting on it for years, and industry associations had been pushing back against it just as long. But its implementation crystallized something that many in the NHP sector had been hoping to avoid: a clear regulatory signal that the low-friction, low-cost licensing environment of the early NHPR era is drawing to a close.

Under the current fee structure, small businesses — those with Canadian gross annual revenue under $5 million — receive a 25% reduction on applicable fees. That concession acknowledges the burden these costs place on smaller manufacturers, many of whom operate with product portfolios in the dozens or hundreds of individual SKUs. But for mid-size and larger organizations, there’s no discount. And the fees apply to each individual product license application, which means an active portfolio generates meaningful compliance costs with every submission cycle.

The practical effect has already started to reshape how organizations approach licensing. Companies that once submitted product license amendments with little internal scrutiny are now doing genuine cost-benefit analysis before each submission. That’s arguably what Health Canada intended. A fee-based system creates a natural pressure toward better dossier preparation and fewer speculative amendments. But it also means that organizations with historically underprepared submission processes are suddenly exposed.

What Health Canada’s Self-Care Framework Would Actually Change About NHP Licensing

The fee regulations are one piece of a larger puzzle. The broader initiative — Health Canada’s Self-Care Framework — has been the subject of public consultation documents and concept papers since 2017, when the directorate began formally exploring how to modernize the regulation of self-care products across Canada.

The core idea is a risk-based continuum. Rather than maintaining hard-edged regulatory silos between natural health products, non-prescription drugs, and cosmetics, the proposed framework would classify products on a spectrum based on their potential health risk. Lower-risk products would access a streamlined licensing pathway. Products making stronger or more novel therapeutic claims would face a review process closer to what currently applies to non-prescription drugs.

In practice, this would have implications in three specific areas:

Licensing pathways and classification. The NPN and DIN-HM product designations that NHP manufacturers know today could eventually give way to a more nuanced classification system. Products currently holding NHP licenses but making meaningful health claims — particularly those that push the boundaries of existing Health Canada monographs — are the most exposed to reclassification under a risk-tiered model.

Evidence requirements. Under a risk-based model, the evidence needed to support a product license varies by where a product lands on the risk continuum. Lower-risk products may continue to rely on bibliographic evidence and recognized monographs. But products with stronger claims or novel ingredients would face requirements approaching those applied to non-prescription drugs — meaning randomized controlled trial data or peer-reviewed systematic reviews rather than traditional use documentation alone.

Post-market surveillance obligations. One of the most consistent themes across all the Self-Care Framework consultation rounds is a significantly more active post-market regime. The framework contemplates enhanced adverse event reporting timelines and a greater expectation that license holders are actively monitoring for safety signals — not just waiting for complaints to come in. For organizations without a functioning pharmacovigilance infrastructure, this is the area with the steepest implementation curve.

The implementation timeline has been a moving target. Health Canada has been clear that the modernization is a priority, but the regulatory process in Canada is deliberately paced — significant amendments to the NHPR require proposed rulemaking in the Canada Gazette, comment periods, and often multiple rounds of revision before they become law. Organizations waiting for a single announcement that everything changes on a specific date will likely be waiting through several more consultation rounds first.

Canada GMP Requirements for NHP Sites: Where the Bar Is Rising

Separate from the Self-Care Framework, there’s been a quieter but equally real shift in how Health Canada approaches GMP inspections of natural health product manufacturing sites.

The current regulatory basis for NHP manufacturing is the Natural Health Products (Good Manufacturing Practices) Regulations, which are distinct from the pharmaceutical GMP requirements in Division 2 of Part C of the Food and Drug Regulations. NHP GMP has historically been less prescriptive than pharmaceutical C.02 GMP. There’s no ICH Q10 pharmaceutical quality system overlay, the validation requirements are less granular, and the documentation expectations have been interpreted with more flexibility. For many companies, this made NHP site licensing a considerably lower-effort proposition than obtaining a Drug Establishment Licence (DEL).

That gap is narrowing. Health Canada inspectors visiting NHP sites in recent years have been applying interpretations of the GMP regulations that look increasingly like pharmaceutical inspection logic. Written procedures, change control documentation, out-of-specification investigation records, and supplier qualification programs are areas where inspectors have become noticeably more exacting — even when the underlying regulatory text doesn’t explicitly require the level of formality that pharmaceutical inspectors routinely demand.

A few specific areas where NHP manufacturers are encountering friction during inspections:

Supplier qualification programs. Health Canada expects that incoming raw material suppliers are evaluated, not just tested on a lot-by-lot basis. An approved supplier list backed by qualification records is increasingly treated as an expectation, not a discretionary best practice.

Batch record integrity. Where batch records exist, inspectors expect them to reflect contemporaneous entries — what actually happened, entered in real time — rather than records that appear to have been completed retrospectively.

Environmental monitoring for botanical manufacturers. Sites that handle plant-based materials have seen particular scrutiny around the completeness of their environmental monitoring programs. A pest control log that exists on paper but hasn’t been updated in 90 days is not a defensible document.

None of this formally departs from what the existing Canada GMP text requires for NHPs. But the practical effect for manufacturers is that operating to a loose interpretation of those requirements is a less defensible position than it was five years ago — and significantly less defensible than it will likely be five years from now.

How to Position Your Organization for What’s Coming

Given where the regulatory environment is heading, there are four areas that NHP manufacturers and importers should be working on now, regardless of when any specific framework change formally takes effect.

Review your product license portfolio systematically. If you’re operating on product licenses issued before 2020, it’s worth confirming that your labels, formulations, and evidence dossiers still align with Health Canada’s current interpretive expectations. The directorate’s views on supporting evidence have evolved, and a license that passed review under older standards may be harder to amend under current conditions.

Conduct an evidence audit before you’re asked to defend your dossiers. Under a risk-based model, the evidence supporting each health claim carries more weight. If your products make claims that don’t sit squarely within a recognized Health Canada monograph, you should understand whether your supporting evidence could withstand a more demanding review standard — before that standard is formally in place.

Treat your GMP program as a living quality system, not a one-time certification. Organizations that maintain their quality systems actively — with regular internal audits, functional CAPA processes, and current SOPs — are in a materially better position when an inspector arrives than those that pull out the quality manual only when an inspection date is confirmed.

Work with testing partners who understand the Canadian regulatory context. Product testing for NHP licenses isn’t just about passing specifications. It’s about generating data in a manner that Health Canada will accept. Certificates of analysis from accredited laboratories, method validation documentation, and chain-of-custody records matter. Choosing analytical partners who understand the specific requirements of NHP submissions in Canada — rather than just capable labs with no regulatory context — makes a real difference when submissions come under scrutiny.

The regulatory direction is clear even if the timeline isn’t. Health Canada is moving toward a more rigorous, more risk-differentiated approach to the regulation of natural health products in Canada. Organizations that start building the compliance infrastructure now — before it becomes legally mandatory — are the ones that won’t be scrambling when the next phase of the Self-Care Framework lands.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• ISO 17025 Accreditation and Supplement Testing in the US — How American supplement manufacturers use accredited contract labs to meet FDA and FTC labelling standards.
• Navigating EU Cosmetics and Self-Care Regulation Under 1223/2009 — For NHP brands considering expansion into European markets, a detailed look at how the EU classifies and licenses self-care products differently from Canada.